Initial placement or subsequent movement of Anaphylm showed no impact on epinephrine pharmacokinetics (PK) or pharmacodynamics (PD), with all results comparable to epinephrine injection Data ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Aquestive Therapeutics’ Anaphylm begins to dissolve on ...
Please provide your email address to receive an email when new articles are posted on . Aquestive aims to submit a new drug application in the first quarter of 2025. The company hopes to launch in ...
A Prescription Drug User Fee Act target date of January 31, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for epinephrine ...
VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results